Revital Mandil–Levin
Directeur/Membre du Conseil chez NEUROSENSE THERAPEUTICS LTD.
Fortune : 35 943 $ au 30/04/2024
Profil
Revital Mandil–Levin is the founder of Nanocarry Therapeutics Ltd.
She is currently the Director at Neurosense Therapeutics Ltd.
She previously worked as the Vice President-Corporate Development at NeuroDerm Ltd.
from 2014 to 2018.
Prior to that, she was the Vice President-Business Development at HealOr Ltd.
from 2004 to 2013.
She also served as the Manager-Business Development at Geffen Residence & Renewal Ltd.
In 2018 to 2019, Dr. Mandil–Levin held the position of Chief Business Development Officer at CollPlant Biotechnologies Ltd.
She then became the Vice President-Corporate Development at Anima Biotech, Inc. from 2019 to 2020.
Dr. Mandil–Levin obtained her graduate and doctorate degrees from Bar-Ilan University.
She also holds an MBA from The College of Management Academic Studies.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/04/2024 | 28 526 ( 0,16% ) | 35 943 $ | 30/04/2024 |
Postes actifs de Revital Mandil–Levin
| Sociétés | Poste | Début |
|---|---|---|
| NEUROSENSE THERAPEUTICS LTD. | Directeur/Membre du Conseil | 01/01/2022 |
Nanocarry Therapeutics Ltd.
 Nanocarry Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Nanocarry Therapeutics Ltd. is a company based in Nes-Ziona, Israel. Nanocarry is developing a new class of therapeutics using bioengineered nanoparticles to treat oncology indications and brain diseases. The Israeli company's proprietary "plug and play" approach allows for easy modification to deliver a wide array of biologics safely and effectively to the brain and beyond. Nanocarry's first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer. The company aims to extend the reach of biological therapeutics to the brain to tackle CNS diseases head-on, pioneering a multidisciplinary approach that overcomes the blood-brain barrier. The company was founded by Rachela Popovtzer, Oshra Betzer, and Revital Mandil-Levin, with Revital Mandil-Levin serving as the CEO since incorporation. | Directeur Général | - |
Anciens postes connus de Revital Mandil–Levin
| Sociétés | Poste | Fin |
|---|---|---|
Anima Biotech, Inc.
 Anima Biotech, Inc. Pharmaceuticals: MajorHealth Technology Anima Biotech, Inc. develops translation control therapeutics, a new class of drugs that specifically control protein translation as a novel strategy against hard and undruggable targets. The firm?s platform combines new biology with proprietory image analysis and big data software. The company was founded Yochi Slonim and Zeev Smilansky and is headquartered in Bernardsville, NJ. | Corporate Officer/Principal | 01/11/2020 |
| COLLPLANT BIOTECHNOLOGIES LTD. | Corporate Officer/Principal | 01/02/2019 |
| NEURODERM LTD | Corporate Officer/Principal | 01/02/2018 |
HealOr Ltd.
 HealOr Ltd. Pharmaceuticals: MajorHealth Technology HealOr Ltd. develops and commercializes proprietary biochemical regulatory therapeutics impacting skin cells properties for the purpose of treating various skin pathologies. Its leading drug, HO/03/03, is currently undergoing Phase II/III clinical trials in the United States and India. The company is also establishing a first-in-class therapeutic pipeline for additional skin pathologies such as chronic and acute wounds, dry skin, acne, psoriasis, and others. HealOr was founded by Tamar Tennenbaum in 2002 and is headquartered in Rechovot, Israel. | Corporate Officer/Principal | 01/12/2013 |
| GEFFEN RESIDENCE & RENEWAL LTD | Corporate Officer/Principal | - |
Formation de Revital Mandil–Levin
| Bar-Ilan University | Doctorate Degree |
| The College of Management Academic Studies | Masters Business Admin |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| GEFFEN RESIDENCE & RENEWAL LTD | Process Industries |
| COLLPLANT BIOTECHNOLOGIES LTD. | Health Technology |
| NEUROSENSE THERAPEUTICS LTD. | Health Technology |
| Entreprise privées | 4 |
|---|---|
NeuroDerm Ltd.
 NeuroDerm Ltd. BiotechnologyHealth Technology NeuroDerm Ltd. operates as a clinical-stage pharmaceutical company. It engages in the development of next-generation treatments for central nervous system disorders. The company was founded by Eliahu Heldman on March 18, 2003 and is headquartered in Rehovot, Israel. | Health Technology |
HealOr Ltd.
HealOr Ltd. Pharmaceuticals: MajorHealth Technology HealOr Ltd. develops and commercializes proprietary biochemical regulatory therapeutics impacting skin cells properties for the purpose of treating various skin pathologies. Its leading drug, HO/03/03, is currently undergoing Phase II/III clinical trials in the United States and India. The company is also establishing a first-in-class therapeutic pipeline for additional skin pathologies such as chronic and acute wounds, dry skin, acne, psoriasis, and others. HealOr was founded by Tamar Tennenbaum in 2002 and is headquartered in Rechovot, Israel. | Health Technology |
Anima Biotech, Inc.
Anima Biotech, Inc. Pharmaceuticals: MajorHealth Technology Anima Biotech, Inc. develops translation control therapeutics, a new class of drugs that specifically control protein translation as a novel strategy against hard and undruggable targets. The firm?s platform combines new biology with proprietory image analysis and big data software. The company was founded Yochi Slonim and Zeev Smilansky and is headquartered in Bernardsville, NJ. | Health Technology |
Nanocarry Therapeutics Ltd.
Nanocarry Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Nanocarry Therapeutics Ltd. is a company based in Nes-Ziona, Israel. Nanocarry is developing a new class of therapeutics using bioengineered nanoparticles to treat oncology indications and brain diseases. The Israeli company's proprietary "plug and play" approach allows for easy modification to deliver a wide array of biologics safely and effectively to the brain and beyond. Nanocarry's first products in development are for brain metastases of HER2+ breast cancer and non-small cell lung cancer. The company aims to extend the reach of biological therapeutics to the brain to tackle CNS diseases head-on, pioneering a multidisciplinary approach that overcomes the blood-brain barrier. The company was founded by Rachela Popovtzer, Oshra Betzer, and Revital Mandil-Levin, with Revital Mandil-Levin serving as the CEO since incorporation. | Commercial Services |